Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-08-25
2004-01-27
Ketter, James (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S04400A
Reexamination Certificate
active
06683047
ABSTRACT:
BACKGROUND OF THE INVENTION
References are cited throughout the specification. These references in their entirety are incorporated by reference into the specification to more fully describe the state of the art to which it pertains.
Positive and negative control of gene expression by retinoids is mediated by nuclear receptors that are part of a large family of regulatory proteins including the steroid and thyroid hormone receptors, the vitamin D receptor, and the retinoid receptors (RAR). This latter group comprises three retinoic acid (RA) receptors: RAR&agr;, &bgr; and &ggr;, that contain highly conserved DNA and ligand binding domains. In addition a more distantly related receptor, RXR, appears to be activated by a RA metabolite.
Nuclear receptors function as transcriptional activators in the presence of their ligand. RARs, like the thyroid hormone receptors, do not require ligand binding for nuclear localization and specific DNA interaction. Until the subject invention, interaction with specific DNA sequences was thought to be essential for all regulatory functions of nuclear receptors.
Since glucocorticoids and RA are known to repress members of the collagenase family they have promise as therapeutic agents in rheumatoid arthritis where proteinases, such as collagenase and stromelysin, play an important role in joint destruction. Collagenase is the only enzyme known to cleave collagen, a major structural component of bone and cartilage destroyed by the enzyme. Retinoids inhibit the production of collagenase by synovial cells while the tumor promoter 12-0-tetradecanoyl-phorbol-13-acetate (TPA) and the inflammatory mediators interleukin 1 (IL1) and tumor necrosis factor alpha (TNF&agr;) stimulate collagenase secretion and transcription.
Thus, while the RA and glucocorticoid nuclear receptors are known to repress members of the collagenase family, the-mechanism of this repression was not known. A logical presumption was that the repression relates to the receptors known ability to bind DNA. However, the present invention provides the surprising discovery that these nuclear receptors actually inhibit transcription through a protein/protein interaction with AP-1, a protein complex composed of Jun homodimers and Jun/Fos heterodimers. Hence, a major discovery that regulatory function of nuclear receptors are mediated by a mechanism that does not involve direct binding to DNA is provided. This discovery provides a mechanism through which arthritis and cancer can be treated.
SUMMARY OF THE INVENTION
This invention provides a method of inhibiting the transcription of a gene, which is activated by AP-1 or an AP-1 component, comprising binding AP-1 or the component with a nuclear receptor so as to prevent the binding of AP-1 to the gene. The nuclear receptor can be the retinoic acid receptor, glucocorticoid receptor, vitamin D3 receptor, thyroid receptor, or the estrogen receptor.
Also provided is a composition of matter comprising AP-1 or an AP-1 component bound to a nuclear receptor. These methods and compositions can be used to identify and screen for new ligands of nuclear receptors useful for treatment of arthritis and cancer.
REFERENCES:
patent: 5639592 (1997-06-01), Evans
patent: 0552202 (1996-01-01), None
patent: WO 92/05447 (1992-04-01), None
Bailly et al., “Retinoic Acid Inhibits the Production of Collagenase by Human Epidermal Keratinocytes,”Chemical Abstracts112:48755h, p. 70 (1990).
Brinckerhoff and Harris, “Modulation by Retinoic Acid and Corticosteroids of Collagenase Production by Rabbit Synovial Fibroblasts Treated with Phorbol Myristate Acetate or Poly (Ethylene Glycol),”Biochem. Biophys. Acta. 677:424-432 (1981).
Drouin et al., “Glucocorticoid Receptor Binding to a Specific DNA Sequence is Required for Hormone-Dependent Repression of Pro-Opiomelanocortin Gene Transcription,”Mol. Cell Biol. 9:5305-5314 (1989).
Evans R., “The Steroid and Thyroid Hormone Receptor Superfamily,”Science240:889-895.
Haq et al., “Differential Effects of All-trans and 13-CIS-Retinoic Acid on mRNA Levels of Nuclear Retinoic Acid Receptors in Rat Lung and Liver,”Biochem. Biophys. Res. Comm. 180:1137-1144 (1991).
Haq et al., “Retinoic acid affects the expression of a nuclear retinolc acid receptors in tissues of retinol-deficient rats,”Proc. Natl. Acad. Sci. USA88:8272-8276 (1991).
Jonat et al., “Antitumor Promotion and Antiinflammation: Down-Modulation of AP-1 (Fos/Jun) Activity by Glucocorticoid Hormone,”Cell62:1189-1204 (1990).
Jonat et al., “Positive and Negative Regulation of Collagenase Gene Expression,”Proceedings of the Metalloproteinase Conferencepp. 145-155 (1989).
Krust et al., “A third human retinoic acid receptor, hRAR-&ggr;,”Proc. Natl. Acad. Sci. USA86:5310-5314.
Lafyatis et al., “Interleukin-1 Stimulates and All-Trans-Retinoic Acid Inhibits Collagenase Gene Expression through its 5′ Activator Protein-1-Binding Site,”Mol. Endo. 4:973-980 (1990).
Lafyatis et al., “Interleukin-1 stimulates and all-trans-retinoic acid inhibits collagenase gene expression through its activator protein-1-binding site,”Chemical Abstracts113:150486 (1990).
Lehmann et al., “RAR&ggr;2 Expression is Regulated through a Retinoic Acid Response Element Embedded in Spl Sites,”Mol.&Cell. Biol. 12:2976-2985 (1992).
Mordacq and Linzer, “Co-localization of elements required for phorbol ester stimulation and glucocorticoid repression of proliferin gene expression,”Genes&Dev. 3:760-769 (1989).
Muller et al., “The collagenase gene family in humans consists of at least four members,”Biochem. J. 253:187-192 (1988).
Offringa et al., “Similar effects of adenovirus ElA and glucocorticoid hormones on the expression of the metalloprotease stromelysin,”Nucl. Acids Res. 16:10973-10983 (1988).
Schüle et al., “Functional Antagonism between Oncoprotein c-Jun and the Glucocorticoid Receptor,”Cell62:1217-1226 (1990).
Yang-Yen et al., “Transcriptional Interference between c-Jun and the Glucocorticoid Receptor: Mutual Inhibition of DNA Binding due to Direct Protein-Protein Interaction,”Cell62:1205-1215 (1990).
Karin Michael
Pfahl Magnus
Ketter James
McDermott & Will & Emery
Sandals William
The Burnham Institute
LandOfFree
Method of inhibiting transcription utilizing nuclear receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting transcription utilizing nuclear receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting transcription utilizing nuclear receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3218383